Company: CNTB
Filing Date: 2025-09-10
Form Type: POS AM
Source: 0001193125-25-200186
Chunk: 68

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-09-10
Form: POS AM
Chunk 68
---
 and Industry

| • |     | Our operating results may fluctuate significantly, which makes our future operating results difficult to 
 predict and could cause our operating results to fall below expectations or any guidance we may provide. |

| • |     | We are dependent on the services of our management and other clinical and scientific personnel, and if we are                         
 not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer. |

| • |     | We may encounter difficulties in managing our growth and expanding our operations successfully. |

| • |     | If we have multiple Product Candidates in our clinical pipeline and if we consider a variety of target                                                                                                                                   
 indications, we may expend our limited resources to pursue a particular Product Candidate and fail to capitalize on Product Candidates or indications that may be more profitable or for which there is a greater likelihood of success. |

| • |     | We have incurred and may continue to incur significant costs for our clinical trials for our Product 
 Candidates.                                                                                          |

| • |     | We may be exposed to liabilities under the U.S. Foreign Corrupt Practices Act and similar anti-corruption and                                                                                                                                      
 anti-bribery laws of the PRC and other countries in which we operate, as well as U.S. and foreign export controls, trade sanctions and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in 
 foreign markets and any determination that we have violated these laws could have a material adverse effect on our business or our reputation.                                                                                                     |

| • |     | We are subject to various foreign, federal, and state healthcare laws and regulations, and failure to comply 
 with these laws and regulations could harm our results of operations and financial condition.                |

| • |     | Actual or perceived failures to comply with applicable data protection, privacy and security laws,                                 
 regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition. |

| • |     | Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty                     
 and cost for us to obtain marketing approval for and commercialize our Product Candidates and may affect the prices we may set. |

| • |     | Some of our investments may be subject to review from the Committee on Foreign Investment in the U.S. which 
 may delay or block a transaction from closing.                                                              |

| • |     | If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required 
 to limit commercialization of our products